Wang Kang-Ling, Yap Eng Soo, Goto Shinya, Zhang Shu, Siu Chung-Wah, Chiang Chern-En
1General Clinical Research Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., 11217 Taipei, Taiwan.
2School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Thromb J. 2018 Jan 18;16:4. doi: 10.1186/s12959-017-0155-z. eCollection 2018.
Although the incidence of venous thromboembolism (VTE) in Asian populations is lower than in Western countries, the overall burden of VTE in Asia has been considerably underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations include the limited availability of epidemiological data in Asia, ethnic differences in the genetic predisposition to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. The clinical assessment, diagnostic testing, and therapeutic considerations for VTE are, in general, the same in Asian populations as they are in Western populations. The management of VTE is based upon balancing the treatment benefits against the risk of bleeding. This is an especially important consideration for Asian populations because of increased risk of intracranial hemorrhage with vitamin K antagonists. Non-vitamin K antagonist oral anticoagulants have shown advantages over current treatment modalities with respect to bleeding outcomes in major phase 3 clinical trials, including in Asian populations. Although anticoagulant therapy has been shown to reduce the risk of postoperative VTE in Western populations, VTE prophylaxis is not administered routinely in Asian countries. Despite advances in the management of VTE, data in Asian populations on the incidence, prevalence, recurrence, risk factors, and management of bleeding complications are limited and there is need for increased awareness. To that end, this review summarizes the available data on the epidemiology, risk stratification, diagnosis, and treatment considerations in the management of VTE in Asia.
尽管亚洲人群静脉血栓栓塞症(VTE)的发病率低于西方国家,但亚洲VTE的总体负担一直被严重低估。与西方人群相比,亚洲人群VTE患病率较低的原因可能包括亚洲流行病学数据有限、VTE遗传易感性的种族差异、诊断不足、对血栓性疾病的认识不足,以及亚洲患者中可能症状性VTE较少。一般来说,亚洲人群VTE的临床评估、诊断检测和治疗考量与西方人群相同。VTE的管理基于平衡治疗益处与出血风险。对于亚洲人群而言,这是一个尤为重要的考量因素,因为维生素K拮抗剂会增加颅内出血风险。在包括亚洲人群在内的主要3期临床试验中,非维生素K拮抗剂口服抗凝药在出血结局方面已显示出优于现有治疗方式的优势。尽管抗凝治疗已被证明可降低西方人群术后VTE的风险,但亚洲国家并未常规进行VTE预防。尽管VTE管理取得了进展,但亚洲人群中关于VTE发病率、患病率、复发率、危险因素和出血并发症管理的数据有限,仍需要提高认识。为此,本综述总结了亚洲VTE管理中关于流行病学、风险分层、诊断和治疗考量的现有数据。